





















720The relationship of walking distances estimated
by the patient, on the corridor and on a treadmill,
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Objective: Physicians and patients consider the limited walking distance and perceived disability when they make decisions
regarding (invasive) treatment of intermittent claudication (IC). We investigated the relationship between walking
distances estimated by the patient, on the corridor and on a treadmill, and the Walking Impairment Questionnaire (WIQ)
in patients with IC due to peripheral arterial disease.
Methods: This was a single-center, prospective observational cohort study at a vascular laboratory in a university hospital in
the Netherlands. The study consisted of 60 patients (41 male) with a median age of 64 years (range, 44-86 years) with IC
and a walking distance #250 m on a standardized treadmill test. Main outcome measures were differences and Spearman
rank correlations between pain-free walking distance, maximumwalking distance (MWD) estimated by the patient, on the
corridor and on a standardized treadmill test, and their correlation with the WIQ.
Results: The median patients’ estimated, corridor, and treadmill MWD were 200, 200, and 123, respectively (P < .05).
Although the median patients’ estimated and corridor MWD were not signiﬁcantly different, there was a difference on an
individual basis. The correlation between the patients’ estimated and corridor MWD was moderate (r [ 0.61; 95%
conﬁdence interval [CI], 0.42-0.75). The correlation between patients’ estimated and treadmill MWD was weak (r [
0.39; 95%, CI 0.15-0.58). Respective correlations for the pain-free walking distance were comparable. The patients’
estimated MWD was moderately correlated with WIQ total score (r[ 0.63; 95%, CI 0.45-0.76) and strongly correlated
with WIQ distance score (r[ 0.81; 95% CI, 0.69-0.88). The correlation between the corridor MWD and WIQ distance
score was moderate (r [ 0.59; 95% CI, 0.40-0.74).
Conclusions: Patients’ estimated walking distances and on a treadmill do not reﬂect walking distances in daily life.
Instruments that take into account the perceived walking impairment, such as the WIQ, may help to better guide and
evaluate treatment decisions. (J Vasc Surg 2013;57:720-7.)Treatment of patients with intermittent claudication
(IC) is aimed at improving pain-free walking distance
(PFWD), and subsequently quality of life, and at secondary
prevention of cardiovascular events by controlling risk
factors for atherosclerosis.1 The decision for (invasive)the Department of Vascular Surgerya and Department of Radiology,b
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walking distance as perceived by the patient. An estimation
of the pain-free or absolute walking distance can help guide
decision making, but this is not as easy as it seems. It has
been shown in one study that it is difﬁcult for patients to
estimate their actual walking distance on a corridor.2 Stan-
dardized walking tests on a treadmill are widely used for
a more objective assessment of walking distances and to
evaluate the result of treatment both in practice and in
research. However, walking on a treadmill is an artiﬁcial
condition that is quite different from the patient’s daily
walk on a mostly ﬂat surface and at his or her own pace.
This discrepancy has been proven in two studies that
reported moderate correlations between walking distances
on a treadmill and on the corridor, and also between
patients’ estimates of walking distances and on
a treadmill.2,3
The Walking Impairment Questionnaire (WIQ) is
a well-validated instrument for expressing perceived
walking impairment in patients with IC.4-8 The WIQ has
been suggested as an alternative to treadmill testing
because of its correlation with changes in claudication
distances on a treadmill.7 However, the correlation
between the WIQ and treadmill walking distances is
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assess walking distances, it would be desirable to have
information on the relation between the WIQ and daily
life walking distances on the ﬂoor. Surprisingly, there is
a paucity of data on this topic. McDermott et al8 found
a moderate correlation between the distance covered
during a 6-minute walking test in a hallway and the WIQ
distance score. Because there are no other studies that
directly relate walking distances on a corridor to the
WIQ, we conducted a study to determine correlations
between walking distances estimated by the patient, on
the corridor and on a treadmill, and their correlation
with the WIQ.
METHODS
Study population and eligibility criteria. The study
was designed as a prospective observational cohort study.
The Medical Ethics Review Committee of our institution
judged that the Medical Research Involving Human
Subjects Act did not apply to our study and waived ofﬁcial
ethical approval by the committee.
All consecutive patients who visited our vascular labo-
ratory between October 2010 and July 2011 for a treadmill
test were informed about the study. We sent all patients
a letter in advance and contacted them 2 days before the
test to ask for their participation. Patients were included
if they were 18 years or older, had complaints of disabling
IC, had a maximum walking distance (MWD) on a tread-
mill test #250 m, had an ankle-brachial index (ABI) <0.9
or a decline in ABI of >0.15 immediately after the tread-
mill test in at least one leg, and gave written informed
consent to participate in the study. Patients were excluded
if the treadmill test could not be carried out due to severe
comorbidity or walking difﬁculties, and if the walking
distance on the treadmill was >250 m. Other exclusion
criteria were participation in another study and insufﬁcient
knowledge of the Dutch or English language. Baseline
characteristics and patients’ medical history and cardiovas-
cular risk factors were recorded.
Ankle-brachial index measurements. A handheld
Doppler probe (Nicolet VasoGuard; Viasys Healthcare
Systems, Madison, Wisc) was used to obtain systolic pres-
sures in the right and left brachial, dorsalis pedis, and poste-
rior tibial arteries. The ABI was deﬁned as the ratio of the
highest of the ipsilateral dorsalis pedis and posterior tibial
artery pressures and the highest systolic (left or right)
brachial artery pressure.9 The ABI was recorded at rest
and after a treadmill test.
Assessment of walking distances. The PFWD was
deﬁned as the walking distance until the onset of claudica-
tion pain. The MWD was deﬁned as the walking distance
until intolerable claudication pain forced the patient to
stop. Assessments were always in the same sequence. If
patients qualiﬁed for the study after the treadmill test,
they were asked to estimate their PFWD and MWD in daily
life, and then they performed the corridor walking test.
“Treadmill” walking distances. We used two
different treadmill tests depending on availability. Allocationof the treadmill test was not randomized. One treadmill
test was according to the TransAtlantic Inter-Society
Consensus (TASC) II recommendations at a speed of
3.2 km/h and an incline of 10% (test I).1 The other
test was the regular treadmill test in our clinic at a speed
of 3.0 km/h and an incline of 8% (test II). During the
tests, PFWD and MWD were recorded. The MWD at
each treadmill test was set at 250 m, as is usual in our
clinic. Patients were blinded to their PFWD and MWD
on the treadmill in an attempt to minimize bias for the
other assessments.
“Estimated” walking distances. All patients were
asked to estimate their PFWD and MWD in daily life in
meters (patients’ estimated walking distances) after they
could be included in our study and gave consent to
participate.
“Corridor” walking distances. After the treadmill
test, patients rested for at least 15 minutes and then were
transported in a wheelchair to a 100-m walking course
that was constructed on a corridor in our clinic. Every
meter on this course was ticked, enabling us to measure the
walking distances. The patients started at the 50-m tick and
walked counterclockwise in order to try to keep the patient
uninformed about the covered distance. Patients were
instructed to walk at their own pace during corridor
walking. We did not set a minimum or maximum distance.
We recorded PFWD and MWD, and the time until PFWD
and MWD, which allowed us to calculate the average
walking speed until onset of pain, until the patient stopped,
and the average overall walking speed.
The WIQ. The WIQ is a brief questionnaire with
three components: estimation of walking distance, walking
speed, and stair climbing abilities. For each component,
patients rank the degree of difﬁculty for the corresponding
task on a Likert scale, which ranges from 4 (no difﬁculty) to
0 (unable to perform the task). The WIQ distance, speed,
stair climbing, and total scores range from 0% and 100%.10
The Dutch version of the WIQ has been shown to be
a valid, reliable, and clinically relevant instrument for
assessing walking impairment in patients with IC.6,7
Statistical analysis. For baseline characteristics, differ-
ences in distribution of categorical variables were tested
with the Fisher exact test or c2 test, and differences in
continuous variables with an unpaired t-test or Mann-
Whitney test where appropriate.
We planned to do an analysis of the walking distances
on a group level, comparing medians, and on an individual
basis with correlation analysis.
The patients’ estimated, corridor, and treadmill PFWD
and MWD are expressed in meters. Assuming a non-
normal distribution of continuous variables, we used Fried-
man two-way analysis of variance test to determine
differences between the three assessments, which when
applicable were further tested in two by two comparisons
with the Wilcoxon signed rank test for paired data.
Correlations and 95% conﬁdence interval (CI)
between PFWD and MWD at the three assessments were
calculated with a Spearman rank correlation test, assuming
Fig 1. Flow diagram of patient inclusion.
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ered to be strong if r $ 0.7, moderate if r is between 0.3
and 0.7, and weak if r is # 0.3.11,12
Correlations and 95% CI between WIQ distance score
and patients’ estimated and corridor MWD, and correla-
tion between WIQ speed score and corridor speed were
calculated with the Spearman rank correlation test.
All analyses were performed with SPSS version 18.0 for
Windows (SPSS Inc, Chicago, Ill). P < .05 indicated statis-
tical signiﬁcance.
RESULTS
Patients. Between October 2010 and July 2011, 294
patients were referred to our vascular laboratory for a tread-
mill test with ABI measurements (pre- and postexercise)
by physicians from different specialties. Sixty patients
(41 men; median age, 64 years; range, 44-86 years) were
included in our study (Fig 1). Thirty patients completed
treadmill test I, and 30 patients completed treadmill test II.
Demographics and breakdown of baseline characteristics
according to treadmill test are given in Table I and are
typical for a population of claudicants. Table I also lists
the breakdown of baseline characteristics according to
treadmill test. There were differences between groupswith regard to age, body mass index, and previous inter-
ventions, although these differences were not statistically
signiﬁcant.
Walking distances. Walking distances are listed in
Table II. Patients who did test II had shorter walking
distances than did those who did test I. Table III lists the
differences and correlations between the assessments for
both tests together and separately. The median patients’
estimated, corridor, and treadmill MWD were 200, 200,
and 123 m, respectively, which was a signiﬁcant difference.
The patients’ estimated and corridor median PFWD and
MWD were signiﬁcantly longer than the median walking
distances on the treadmill. The median patients’ estimated
PFWD and MWD were not signiﬁcantly different from the
PFWD and MWD on the corridor. The PFWD and MWD
for both tests together (n ¼ 60) are shown in Fig 2.
There were differences, however, on an individual
basis. The moderate correlations between the patients’
estimated and corridor PFWD and MWD are demon-
strated in Table III and Fig 3. The correlations between
treadmill and corridor walking distances were moderate
as well. The correlations between patients’ estimated and
treadmill PFWD and MWD were weak. The reason for
apparently discordant results for the analysis on the group
Table I. Baseline characteristics
Demographics Both tests (n ¼ 60) Test Ia (n ¼ 30) Test IIb (n ¼ 30) P valuec
Patient characteristics, median (range)
Age, years 64 (44-86) 62 (44-85) 66 (48-82) .23
Body mass index 26 (19-36) 25 (21-36) 28 (19-36) .10
Patient characteristics, No. (%)
Male 41 (68) 22 (73) 19 (63) .58
Diabetes mellitus 25 (42) 12 (40) 13 (43) 1
Hypertension 36 (60) 18 (60) 18 (60) 1
Hyperlipidemia 35 (58) 19 (63) 16 (53) .60
Smoking
Current 23 (38) 15 (50) 8 (35) .11
Former 20 (33) 10 (33) 10 (33) 1
Never 17 (28) 5 (17) 12 (40) .09
Cardiovascular history
None 40 (67) 20 (33) 20 (33) 1
NYHA classiﬁcation I 10 (17) 6 (20) 4 (13) .73
NYHA classiﬁcation II 9 (15) 3 (10) 6 (20) .47
NYHA classiﬁcation III 1 (2) 1 (3) 0 (0) 1
Chronic obstructive pulmonary disease 11 (18) 6 (20) 5 (17) 1
Previous transient ischemic attack or stroke 6 (10) 3 (10) 3 (10) 1
Positive family history 34 (57) 16 (53) 18 (60) .79
History of orthopedic disease 10 (17) 6 (20) 4 (13) .73
Previous treatment, No. (%)
No treatment 38 (63) 23 (77) 15 (50) .06
Conservatived 15 (25) 4 (13) 11 (37) .07
Endovascular 19 (32) 6 (20) 13 (43) .10
Surgical 9 (15) 2 (7) 7 (23) .15
Minor amputation 1 (2) 0 (0) 1 (3) 1
ABI, median (range), decimal points
ABI rest left 0.72 (0.15-1.14) 0.71 (0.43-1.07) 0.74 (0.15-1.14) .87
ABI rest right 0.77 (0.15-1.24) 0.78 (0.17-0.96) 0.75 (0.15-1.24) .34
ABI post exercise left 0.37 (0-1.08) 0.36 (0-1.08) 0.46 (0-1.02) .69
ABI post exercise right 0.46 (0-1.21) 0.41 (0-0.73) 0.52 (0-1.21) <.05
ABI, Ankle-brachial index; NYHA, New York Heart Association.
aTest I: 3.2 km/h, 10% incline.
bTest II: 3.0 km/h, 8% incline.
cConsidering c2 test, Fisher exact test if categorical variables, and unpaired t-test or Mann-Whitney test if continuous variables for differences between tests I
and II where appropriate. P < .05 indicates statistically signiﬁcant difference.
dConservative treatment indicates supervised exercise therapy or exercise advice.
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(correlation) is a possible systematic difference between
two measurements, which can explain the signiﬁcant differ-
ence in walking distances; also, these measurements can be
moderately correlated on an individual level.
Correlation with WIQ scores. The WIQ scores and
correlations with walking distances are given in Tables II
and IV, respectively. Patients who did test II had lower
WIQ scores than did those who did test I. The patients’
estimated MWD was strongly correlated with the WIQ
distance score and moderately with the WIQ total score.
The WIQ distance score correlated moderately with the
corridor MWD and poorly with the treadmill MWD. The
WIQ speed score correlated moderately with the average
overall walking speed on the corridor.
Walking speed. Walking speedon the corridor is listed in
Table II. All corridor walking speeds (average walking speed
until onset of pain [pain-free speed], speed until the patient
stopped [pain speed], and average overall walking speed) were
higher than both treadmill test speeds (3.0 and 3.2 km/h).DISCUSSION
Physicians and patients consider the limitations in
PFWD and MWD and perceived disability when they
make decisions regarding (invasive) treatment for IC.
Self-reported walking distances do not seem reliable in
this respect, perhaps because it is simply difﬁcult to estimate
distances for patients with claudication or any person.13 We
found that, on aggregate, there were no signiﬁcant differ-
ences in patients’ estimated and corridor walking distances
in our study, but that on an individual level they were
moderately correlated. Although one would expect claudi-
cants who experience their limited walking distance every
day to know how far they can walk, they cannot reliably
estimate their corridor walking distance. This ﬁnding is in
line with a previous study.2
Unfortunately, treadmill testing is not a more objective
assessment of walking distance than self-reported walking
distances, nor is it more reliable. Our study conﬁrms the
moderate correlation between walking distance on a tread-
mill and on the corridor. Distances covered on a treadmill
Table II. Assessments
Assessments Both tests (n ¼ 60) Test Ia (n ¼ 30) Test IIb (n ¼ 30) P valuec
Walking distances, m
Estimated PFWD 100 (20-500) 150 (25-500) 73 (20-300) <.01
Estimated MWD 200 (20-1000) 200 (30-1000) 100 (20-1000) .06
Corridor PFWD 81 (20-452) 95 (31-452) 73 (20-227) .06
Corridor MWD 200 (25-1100) 298 (84-1100) 157 (25-500) <.01
Treadmill PFWD 55 (10-170) 63 (20-130) 50 (10-170) .20
Treadmill MWD 123 (45-250) 130 (50-250) 110 (45-250) .16
WIQ scores, percentage
WIQ distance 11 (0-80) 15 (2-59) 8 (0-80) .11
WIQ speed 31 (0-100) 35 (0-100) 25 (0-83) .36
WIQ stair climbing 40 (0-100) 50 (0-100) 35 (0-88) .08
WIQ total score 32 (0-83) 37 (5-80) 24 (0-83) .09
Corridor walking speed, km/h
Corridor pain-free speed 4.1 (2.0-5.4) 4.4 (2.8-5.2) 4.0 (2.0-5.4) <.05
Corridor pain speed 3.9 (1.5-5.1) 4.0 (2.6-5.1) 3.6 (1.5-5.1) <.01
Corridor average overall speed 4.0 (2.0-5.3) 4.2 (2.8-5.1) 3.9 (2.0-5.3) <.05
MWD, Maximum walking distance; PFWD, pain-free walking distance; WIQ, Walking Impairment Questionnaire.
Values are given as median (range).
aTest I: 3.2 km/h, 10% incline.
bTest II: 3.0 km/h, 8% incline.
cConsidering c2 test, Fisher exact test if categorical variables, and unpaired t-test or Mann-Whitney test if continuous variables for differences between tests I
and II where appropriate. P < .05 indicates statistically signiﬁcant difference.

















(95% CI), P value
PFWD
Both tests 55 81 100 .000 Treadmill-corridor 0.52 (0.30-0.68), P ¼ .000
(10-170) (20-452) (20-500) .000 Treadmill-estimated 0.23 (0.03-0.46), P ¼ .078
.029 Corridor-estimated 0.51 (0.29-0.67), P ¼ .000
MWD
Both tests 123 200 200 .000 Treadmill-corridor 0.52 (0.30-0.68), P ¼ .000
(45-250) (25-1100) (20-1000) .000 Treadmill-estimated 0.39 (0.15-0.58), P ¼ .002
.245 Corridor-estimated 0.61 (0.42-0.75), P ¼ .000
Test I: 3.2 km/h, 10% incline
PFWD
Test I 63 95 150 .000 Treadmill-corridor 0.37 (0.02-0.65), P ¼ .042
(20-130) (31-452) (25-500) .000 Treadmill-estimated 0.40 (0.04-0.66), P ¼ .030
.052 Corridor-estimated 0.59 (0.29-0.78), P ¼ .001
MWD
Test I 130 298 200 .000 Treadmill-corridor 0.50 (0.17-0.73), P ¼ .005
(50-250) (84-1100) (30-1000) .000 Treadmill-estimated 0.36 (0.00-0.64), P ¼ .048
.061 Corridor-estimated 0.57 (0.26-0.77), P ¼ .001
Test II: 3.0 km/h, 8% incline
PFWD
Test II 50 73 73 .001 Treadmill-corridor 0.62 (0.34-0.80), P ¼ .000
(10-170) (20-227) (20-300) .018 Treadmill-estimated 0.01 (0.37-0.36), P ¼ .980
.285 Corridor-estimated 0.27 (0.10-0.58), P ¼ .146
MWD
Test II 110 157 100 .002 Treadmill-corridor 0.58 (0.28-0.78), P ¼ .001
(45-250) (25-500) (20-1000) .041 Treadmill-estimated 0.35 (0.01-0.63), P ¼ .057
.773 Corridor-estimated 0.56 (0.25-0.76), P ¼ .001
CI, Conﬁdence interval; MWD, maximum walking distance; PFWD, pain-free walking distance.
aConsidering a paired t-test or Wilcoxon signed rank test for differences between walking distances where appropriate. P < .05 indicates statistically signiﬁcant
difference.
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estimates. In addition, patients walked faster on the corridor
than on the treadmill. Thus, treadmill testing does not reﬂectwalking in daily life. This is particularly the case for treadmill
tests with an incline, such as we investigated in our study
and are advocated in the TASC II recommendations.1
Fig 2. Median pain-free walking distance (PFWD) and maximum
walking distance (MWD).
Fig 3. Distribution of estimated maximum walking distance
(MWD) to MWD corridor.
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distance score and patients’ estimated MWD. This is not
surprising because the WIQ distance score is derived
from the patients’ estimated walking distance. The correla-
tion between corridor walking distance and the WIQ
distance score was only moderate, as in the study by
McDermott et al.8 This may seem disappointing; however,
the WIQ takes into account the effort it takes for the
patient to walk and the patient’s perceived impairment.
Absolute walking distance may be less important for the
patient. The WIQ total score also incorporates walking
speed and stair climbing, and this score correlated moder-
ately with patients’ estimates of walking distance. As such,
the WIQ total score can identify limitations in daily walking
ability and therefore can be helpful in guiding decisions on
treatment.
The ﬁndings of our study have implications for the
evaluation of outcomes in research and in clinical practice:
patient perception of walking impairment might be moreimportant than walking distance. Although the importance
of patient-reported outcomes is increasingly recognized,
the primary end point in clinical trials in claudicants is
most often the distance covered on treadmill. Only two
trials comparing supervised exercise training (SET) and
percutaneous transluminal angioplasty were powered to
detect differences in quality of life.14,15 All other trials
regarded functional status and quality of life as secondary
end points, if at all.16 The fact that treadmill walking
distance and walking impairment are not directly linked is
clearly illustrated in the CLEVER (Claudication: Exercise
Versus Endoluminal Revascularization) study, a random-
ized trial comparing SET and stenting in claudicants
because of aortoiliac disease.17 Although walking perfor-
mance on a treadmill at 6-month follow-up was better in
patients allocated to SET, patients in the stenting group
had higher WIQ scores, reﬂecting less impairment.
In our opinion, clinical trials should focus less on
performance on treadmill tests and more on the functional
status or generic and disease-speciﬁc quality of life to eval-
uate the treatment of patients with IC. Mays et al18 found
in their recent literature review that in patients with IC, the
generic Short Form 36 (SF-36) and the disease-speciﬁc
WIQ are currently the most used instruments. One also
could consider using such instruments in daily clinical prac-
tice for patients with claudication.
Study limitations. We realize that our study has limi-
tations. We tried to minimize bias by studying a consecutive
series. However, only a small number of patients who may
not represent a general IC population met our inclusion
criteria. This limits the external validity of the study. In
addition, the small sample size compromises the precision
of estimates.
We used two different treadmill protocols, which is
a weakness of the study. Although we did not ﬁnd signif-
icant differences in baseline characteristics, we observed
that patients who did the test at a lower speed and a lesser
incline tended to be older, had a higher body mass index,
and more often had an earlier intervention. This probably
is due to the allocation of new patients to the TASC II
protocol and familiar patients to the usual treadmill
protocol. The more severe disease status was reﬂected by
the shorter walking distances in the familiar patients
despite an easier treadmill test. The difference in patient
disease status does not inﬂuence the correlations between
self-reported and corridor walking distances and the
WIQ. However, applying different treadmill protocols in
different patient groups is likely to lead to different corre-
lations. We found that the correlations between PFWD
and MWD on the treadmill and the corridor were some-
what better in patients with more severe disease who did
the easier treadmill test. These patients also might have
been more familiar with treadmill testing than those who
did the more difﬁcult treadmill test. An advantage of using
two treadmill tests is that we now know that the moderate
correlations between walking distances were consistent
over both treadmill protocols and probably are not a coin-
cidental ﬁnding.
Table IV. WIQ score correlations
WIQ total score WIQ distance score WIQ speed score
Estimated MWDa 0.63 (0.45-0.76), P ¼ .000 0.81 (0.69-0.88), P ¼ .000 —
Corridor MWDa 0.60 (0.42-0.75), P ¼ .000 0.59 (0.40-0.74), P ¼ .000 —
Treadmill MWDa 0.39 (0.15-0.58), P ¼ .002 0.44 (0.21-0.63), P ¼ .000 —
Corridor average overall walking speed 0.47 (0.24-0.64), P ¼ .000 — 0.52 (0.30-0.68), P ¼ .000
MWD, Maximum walking distance; WIQ, Walking Impairment Questionnaire.
Values are given as correlation coefﬁcient (95% conﬁdence interval), P value.
aTreadmill MWD for both treadmill tests 1 and 2 together.
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reproducibility of the different walking tests due to logistic
reasons. It has been reported that there is variation in
walking distance on a treadmill, especially on those with
a ﬁxed speed and incline,19 and it is likely that the same
is true for walking distances on the corridor. As a conse-
quence we do not have information on the robustness of
the found correlations. We attempted to estimate the
walking distance in daily life by measuring the walking
distance on a corridor. Although in our opinion corridor
walking is a reasonable representation of everyday walking,
it is not exactly the same as walking on a crowded pave-
ment or on the street. Global positioning system recordings
might provide more reliable information on outdoor
walking capacity.20,21
Finally, we do not have reason to believe that the study
is biased because the sequence of the walking tests was not
randomized. Patients were blinded to the distance they
covered on the treadmill test, and they were unaware
that they could be included in the study only when the
walking distance on the treadmill was <250 m.
CONCLUSIONS
Patients’ estimated walking distances and on a treadmill
do not reﬂect walking distances in daily life. This ﬁnding
has implications for the indication for treatment of patients
with IC. Instruments that take into account the perceived
impairment, such as the WIQ, may help to better guide
and evaluate treatment decisions, but further research is
needed to deﬁne their role.
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Walking indoor ... * 7 ¼.
50 meters . * 50 ¼.
100 meters . * 100 ¼.
200 meters . * 200 ¼.
275 meters . * 275 ¼.
500 meters . * 500 ¼.
100 meters . *1000 ¼. þ
Subtotal score (d) ¼.






100 meters slow ... * 2 ¼.
100 meters normal . * 4 ¼.
100 meters fast . * 6 ¼.
100 meters running . * 8 ¼. þ
Subtotal score (s) ¼.






Walking 1 stairs ... * 13 ¼.
Walking 2 stairs . * 26 ¼.
Walking 3 stairs . * 39 ¼. þ
Subtotal score (st) ¼.
Score domain stairs walking ¼ subtotal score / 312
WIQ total score
Score Domain distance ¼.
Score Domain speed ¼.
Score Domain stairs walking ¼. þ
Subtotal score all ¼.






0¼ Unable to do
